Shares of PRA Health Sciences Inc. (NASDAQ:PRAH) have earned a consensus recommendation of “Buy” from the eight brokerages that are covering the company. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $53.50.

A number of analysts recently weighed in on PRAH shares. TheStreet raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Monday, November 14th. Zacks Investment Research raised shares of PRA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $65.00 price target on the stock in a report on Wednesday, October 5th. Citigroup Inc. increased their price target on shares of PRA Health Sciences from $55.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, September 22nd. Credit Suisse Group AG reissued a “hold” rating and issued a $50.00 price target on shares of PRA Health Sciences in a report on Thursday, November 3rd. Finally, Jefferies Group reissued a “buy” rating on shares of PRA Health Sciences in a report on Tuesday, September 13th.

PRA Health Sciences (NASDAQ:PRAH) opened at 55.06 on Wednesday. The company has a market cap of $3.38 billion, a P/E ratio of 42.75 and a beta of 0.61. PRA Health Sciences has a 52 week low of $35.60 and a 52 week high of $60.96. The company’s 50-day moving average is $54.94 and its 200-day moving average is $49.68.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, November 2nd. The company reported $0.64 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.64. The business had revenue of $399.80 million for the quarter, compared to analyst estimates of $394.87 million. PRA Health Sciences had a net margin of 4.86% and a return on equity of 21.25%. PRA Health Sciences’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.52 EPS. On average, analysts anticipate that PRA Health Sciences will post $2.47 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Analysts Set PRA Health Sciences Inc. (PRAH) Price Target at $53.50” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2016/11/28/analysts-set-pra-health-sciences-inc-prah-price-target-at-53-50.html.

Large investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of PRA Health Sciences by 34.5% in the third quarter. Price T Rowe Associates Inc. MD now owns 233,768 shares of the company’s stock worth $13,210,000 after buying an additional 59,918 shares during the period. Panagora Asset Management Inc. boosted its stake in shares of PRA Health Sciences by 84.0% in the third quarter. Panagora Asset Management Inc. now owns 103,860 shares of the company’s stock worth $5,869,000 after buying an additional 47,410 shares during the period. Fuller & Thaler Asset Management Inc. acquired a new stake in shares of PRA Health Sciences during the third quarter worth about $124,000. Gotham Asset Management LLC boosted its stake in shares of PRA Health Sciences by 10.1% in the third quarter. Gotham Asset Management LLC now owns 201,501 shares of the company’s stock worth $11,387,000 after buying an additional 18,512 shares during the period. Finally, Iguana Healthcare Management LLC acquired a new stake in shares of PRA Health Sciences during the third quarter worth about $848,000. 99.80% of the stock is owned by institutional investors.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

5 Day Chart for NASDAQ:PRAH

Receive News & Stock Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related stocks with our FREE daily email newsletter.